PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $531,000 | -64.8% | 78,134 | -55.2% | 0.21% | -48.4% |
Q4 2016 | $1,507,000 | +488.7% | 174,408 | +187.9% | 0.40% | +757.4% |
Q2 2016 | $256,000 | -56.8% | 60,575 | -55.4% | 0.05% | -44.7% |
Q1 2016 | $592,000 | -75.7% | 135,803 | -65.9% | 0.08% | -67.7% |
Q4 2015 | $2,441,000 | +572.5% | 398,283 | +527.1% | 0.26% | +651.4% |
Q3 2015 | $363,000 | -83.9% | 63,509 | -79.0% | 0.04% | -84.2% |
Q2 2015 | $2,258,000 | -45.3% | 302,741 | -56.1% | 0.22% | -45.3% |
Q1 2015 | $4,125,000 | +17.7% | 689,759 | +48.7% | 0.40% | +21.0% |
Q4 2014 | $3,506,000 | +2576.3% | 463,740 | +1740.1% | 0.33% | +2936.4% |
Q3 2014 | $131,000 | -65.9% | 25,202 | -71.7% | 0.01% | -63.3% |
Q2 2014 | $384,000 | -37.0% | 88,983 | -40.4% | 0.03% | -25.0% |
Q1 2014 | $610,000 | -26.1% | 149,185 | -3.6% | 0.04% | +2.6% |
Q4 2013 | $825,000 | -15.2% | 154,734 | -20.2% | 0.04% | -11.4% |
Q3 2013 | $973,000 | +101.9% | 193,901 | +79.4% | 0.04% | +120.0% |
Q2 2013 | $482,000 | – | 108,065 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |